✦ LIBER ✦

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

✍ Scribed by Ruben Niesvizky; Scott Ely; Tomer Mark; Sangeeta Aggarwal; Janice L Gabrilove; John J. Wright; Selina Chen-Kiang; Joseph A Sparano

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 355 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25584

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open-label, phase 2 trial of denosuma

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

✍ Ravi Vij; Noemi Horvath; Andrew Spencer; Kerry Taylor; Saroj Vadhan-Raj; Robert 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

Weekly treatment with bortezomib for pat

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; David R. Spigel; John Barton; Cindy Farley; Marshall Schreed 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract ## BACKGROUND. The purpose of the current study was to evaluate the efficacy and toxicity of weekly bortezomib in the treatment of patients with recurrent/refractory multiple myeloma. ## METHODS. A total of 40 patients with multiple myeloma who had received either 1 or 2 previous tre

A phase I safety study of enzastaurin pl

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

✍ Irene M. Ghobrial; Nikhil C. Munshi; Brianna N. Harris; Peipei Shi; Nichole M. P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

Extended follow-up of a phase II trial i

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: : Final time-to-event results from the SUMMIT trial

✍ Paul G. Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jaganna 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

Effect of the histone deacetylase inhibi

Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases

✍ Nadezhda V. Koshkina; Krithi Rao-Bindal; Eugenie S. Kleinerman 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 425 KB 👁 2 views

The addition of interferon or high dose

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma : Phase III Eastern Cooperative Oncology Group clinical trial EST 9486

✍ Martin M. Oken; Traci Leong; Raymond E. Lenhard Jr.; Philip R. Greipp; Neil E. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

## BACKGROUND. Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study suggested that the rates of complete response (CR) and survival were increased with a regimen that alternated IFN with chemothera